Healthcare Industry News: cardiopulmonary
News Release - April 7, 2006
Cardiac Science Ships First Powerheart(R) AED Models That Meet New AHA and ERC Resuscitation GuidelinesBOTHELL, Wash., April 7 (HSMN NewsFeed) -- Cardiac Science Corporation (Nasdaq: CSCX ), a global leader in advanced cardiac monitoring and external defibrillation products, announced today that it has shipped two new models of Powerheart® automated external defibrillators (AEDs) that meet the newly updated American Heart Association (AHA) Guidelines for cardiopulmonary Resuscitation and Emergency Cardiovascular Care, as well as the recently released European Resuscitation Council (ERC) Guidelines for Resuscitation.
All new Powerheart® models will fully incorporate and comply with the new guidelines. Powerheart® AEDs currently in use today are capable of being reconfigured to support the new guidelines and the company plans to offer software updates to existing customers to facilitate implementation of the new guidelines-compliant software in previously deployed Powerhearts during 2006.
Many customers already regard Powerheart® AEDs as the easiest-to-use and most technologically-advanced available. Only Powerheart® AEDs include patented Rescue Ready® technology, a critical "self-monitoring" feature which conducts a daily self-diagnostic test of the battery and internal circuitry, and also confirms that the defibrillator pads are connected and capable of delivering therapy. Since an AED is called upon to potentially save the life of a heart attack victim, it is imperative that advance notice to the user is provided if the device requires service to assure the AED will function when needed to rescue a sudden cardiac arrest victim.
Powerheart® AEDs also incorporate the company's patented RHYTHMx® analysis software, as well as its STAR® biphasic shock technology, which determines, based on each patient's unique physiology, the amount of defibrillation energy needed to successfully restore a victim's heartbeat.
According to the AHA, the odds of surviving sudden cardiac arrest decrease by approximately 10 percent for every minute that passes, and wide deployment of AEDs could save as many as 50,000 lives in the United States annually. AEDs are designed to quickly and easily provide a life-saving defibrillation shock to restore normal heart rhythm to a cardiac arrest victim and, as appropriate, to instruct the user to perform CPR in order to temporarily circulate oxygenated blood to the brain and body of a victim who is unable to sustain circulation. AEDs are currently used by first responders such as police, fire and ambulance personnel. They are also increasingly being deployed at places where people gather or work, such as airplanes, airports, train stations, corporate offices, factories, schools, shopping malls, stadiums, restaurants, casinos and federal, state, municipal and commercial buildings.
About the New AHA Guidelines
The new AHA guidelines are based on the evidence evaluation from the 2005 International Consensus Conference on cardiopulmonary Resuscitation and Emergency Cardiovascular Care, which was hosted by the AHA last year. The guidelines contain recommendations designed to improve survival from sudden cardiac arrest and acute life threatening cardiopulmonary problems. The recommendations in the new guidelines confirm the safety and efficacy of many approaches, acknowledge that other approaches may not be optimal, and recommend new treatments that have undergone evidence evaluation. However, the AHA has emphasized that these new and revised treatment recommendations do not imply that care involving the use of earlier guidelines is unsafe. For more information about the new AHA guidelines, visit the AHA website at www.americanheart.org.
About Cardiac Science Corporation
Cardiac Science Corporation develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, patient monitor -defibrillators and cardiology data management systems. Cardiac Science Corporation also sells a variety of related products and consumables, and provides a comprehensive portfolio of training, maintenance and support services. The company is the successor to various entities that have owned and operated cardiology-related businesses which sold products under the trusted brand names Burdick®, Powerheart®, and Quinton®. Cardiac Science Corporation is headquartered in Bothell, WA, and also has operations in Lake Forest, California, Deerfield, Wisconsin, Shanghai, China, Copenhagen, Denmark and Manchester, United Kingdom.
Forward Looking Statements
This press release contains forward-looking statements. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward looking statements in this press release include those that infer or imply that we will be able to successfully commercialize applications incorporating new diagnostic cardiology techniques. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in the registration statement on Form S-4/A that was filed by Cardiac Science Corporation under the name CSQ Holding Company on July 28, 2005, under the caption "Risk Factors," and in the Annual Reports of Quinton Cardiology Systems, Inc. and Cardiac Science, Inc. on Form 10-K for the year ended December 31, 2004, under the captions "Certain Factors that May Affect Future Results," in Cardiac Science Corporation's Quarterly Report on Form 10-Q for the quarter ended September 30, 2005 under the caption "Certain Factors that May Affect Future Results" and in other documents, we file with the Securities and Exchange Commission. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
Source: Cardiac Science
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.